Juvenescence Limited, a life science and biotech company developing therapies to increase healthy human longevity, raised $50 million in its Series A financing.
Founded in 2016 by Jim Mellon, Dr Greg Bailey, Dr Declan Doogan, Anthony Chow, and Alexander Pickett, the company creates, partners with, and invests in new companies with aging or age-related therapeutics by in-licensing compounds from academia and industry, or forming joint ventures to develop therapeutics for longevity. Its team of researchers and drug developers, led by Dr. Doogan and Dr Annalisa Jenkins, targets projects where Juvenescence holds a significant interest in promising novel technologies and shepherds these therapies toward clinical proof of concept and commercialisation.